Lifestyle Asset Management Inc. Trims Position in United Therapeutics Co. (NASDAQ:UTHR)

Lifestyle Asset Management Inc. lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,714 shares of the biotechnology company’s stock after selling 77 shares during the quarter. United Therapeutics makes up about 0.7% of Lifestyle Asset Management Inc.’s investment portfolio, making the stock its 25th biggest position. Lifestyle Asset Management Inc.’s holdings in United Therapeutics were worth $1,310,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. USA Financial Formulas acquired a new stake in shares of United Therapeutics during the 3rd quarter worth $33,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics during the 3rd quarter worth $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics during the 3rd quarter worth $82,000. MassMutual Private Wealth & Trust FSB increased its holdings in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth $90,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $371.89 on Friday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The business has a 50-day moving average of $365.04 and a 200-day moving average of $355.24. The company has a market capitalization of $16.60 billion, a PE ratio of 16.33, a P/E/G ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter last year, the company posted $5.38 earnings per share. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. On average, equities analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 7,800 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the transaction, the chief financial officer now owns 6,978 shares of the company’s stock, valued at approximately $2,442,300. This trade represents a 52.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christopher Causey sold 510 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. This represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 146,848 shares of company stock valued at $55,165,099. Insiders own 11.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on UTHR shares. LADENBURG THALM/SH SH upped their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. The Goldman Sachs Group increased their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.